VBR - ETF AI Analysis
Top Page
Vanguard Small Cap Value ETF (VBR)
VBR, the Vanguard Small Cap Value ETF, earns a solid overall rating thanks to several strong holdings like Williams-Sonoma, Jabil, Tenet Healthcare, and Omnicom, which show robust financial performance, strategic initiatives, and generally supportive technical trends or reasonable valuations. However, weaker names such as Moderna and Viatris, which face profitability and valuation challenges, along with some holdings showing bearish technical signals, modestly weigh on the fund’s appeal. The main risk factor is exposure to smaller value companies where individual stocks can be volatile and some show signs of overvaluation or financial strain.
VBR vs. SPDR S&P 500 ETF (SPY)
- AUM
- 37.48B
- Region
- North America
- Expense Ratio
- 0.05%
- Beta
- 0.81
- Issuer
- Vanguard
- Inception Date
- Jan 26, 2004
- Dividend Yield
- 1.77%
- Asset Class
- Equity
- Index Tracked
- Morningstar US Small Cap Value TR USD
VBR Summary
Vanguard Small Cap Value ETF (VBR) is a fund that follows the Morningstar US Small Cap Value index, focusing on smaller U.S. companies that appear undervalued based on their current stock prices. It spreads your money across many industries, including financials, industrials, real estate, and health care. Well-known holdings include Moderna and Williams-Sonoma. Investors might consider VBR for long-term growth and diversification, especially if they believe smaller, cheaper companies can outperform over time. However, because it invests in small companies and value stocks, its price can be more volatile and may go up and down sharply with the market.
How much will it cost me?
This ETF has an expense ratio of 0.05%, which means you’ll pay about $0.50 per year for every $1,000 invested. That’s lower than average because it’s a passively managed index fund that tracks a small-cap value benchmark instead of paying managers to pick individual stocks.
What would affect this ETF?
VBR could benefit if the U.S. economy stays healthy, consumer spending remains solid, and small, undervalued companies in sectors like financials, industrials, and consumer cyclical rebound, which may also help top holdings such as Williams-Sonoma and Jabil. On the downside, higher interest rates, a U.S. recession, or stress in areas like real estate and smaller financial firms could hurt small-cap value stocks, while sector-specific issues in health care or technology could weigh on holdings like Moderna and F5.
VBR Top 10 Holdings
VBR’s story is less about one star stock and more about a deep bench of U.S. small-cap value names. Health care is giving the fund a lift, with rising shares of Moderna and Tenet Healthcare helping performance despite their underlying financial challenges. Viatris has also been climbing steadily, adding to that momentum. On the flip side, tech and industrial exposure is more mixed, as lagging moves in F5 and packaging player Smurfit Westrock act like a small weight on the portfolio. Overall, the fund leans into U.S. value across health care, industrials, and consumer names.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 MRNA | Moderna | 0.79% | $506.80M | $91.20B | 987.92% | 59Neutral |
 JBL | Jabil | 0.68% | $440.34M | $27.98B | 23.58% | 73Outperform |
 WSM | Williams-Sonoma | 0.61% | $393.27M | $29.88B | 39.22% | 75Outperform |
 ATO | Atmos Energy | 0.60% | $387.26M | $29.37B | 1.44% | 66Neutral |
 FFIV | F5, Inc. | 0.57% | $369.29M | $18.81B | 36.60% | 74Outperform |
 SW | Smurfit Westrock | 0.53% | $338.85M | $22.70B | 24.46% | 69Neutral |
 TPR | Tapestry | 0.52% | $336.02M | $24.01B | 17.78% | 69Neutral |
 THC | Tenet Healthcare | 0.47% | $301.44M | $21.23B | 40.69% | 74Outperform |
 VTRS | Viatris | 0.46% | $298.15M | $21.73B | 83.22% | 60Neutral |
 OMC | Omnicom Group | 0.46% | $295.75M | $22.69B | 19.00% | 73Outperform |
VBR Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VBR, the sentiment is Positive. The current price of 249.26 is above the 20-day moving average (MA) of 238.83, above the 50-day MA of 239.22, and above the 200-day MA of 233.06, indicating a bullish trend. The MACD of 1.97 indicates Negative momentum. The RSI at 62.69 is Neutral, neither overbought nor oversold. The STOCH value of 78.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VBR.
VBR Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VBR | $249.26 | $257.00(3.11% Upside) | $37.48B | 0.05% | 67Neutral |
 IJR | $142.93 | $170.62(19.37% Upside) | $106.45B | 0.06% | 65Neutral |
 VB | $295.90 | $365.49(23.52% Upside) | $79.16B | 0.03% | 66Neutral |
 IWM | $284.02 | $371.43(30.78% Upside) | $75.63B | 0.19% | 63Neutral |
 AVUV | $124.62 | $141.70(13.71% Upside) | $32.62B | 0.25% | 68Neutral |
 IWN | $218.65 | $268.92(22.99% Upside) | $14.15B | 0.24% | 64Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VBR | Vanguard Small Cap Value ETF | 249.26 | 49.00 | 24.47% | |
| IJR | iShares Core S&P Small Cap ETF | 142.93 | 27.48 | 23.81% | |
| VB | Vanguard Small-Cap ETF | 295.90 | 48.82 | 19.76% | |
| IWM | iShares Russell 2000 ETF | 284.02 | 46.09 | 19.37% | |
| AVUV | Avantis U.S. Small Cap Value ETF | 124.62 | 28.96 | 30.27% | |
| IWN | iShares Russell 2000 Value ETF | 218.65 | 46.88 | 27.29% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.